| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
The purpose of the present study is to develop novel therapies against bladder cancer by inducing endoplasmic reticulum (ER) stress using combinations of the clinically feasible proteasome inhibitor, HIV protease inhibitor, and histone deacetylase inhibitor. The efficacy of 7 combinations were evaluated. The combinations caused apoptosis and inhibited bladder cancer growth by inducing ER stress. The ER stress was induced by the accumulation of unfolded proteins and excessively accumulated unfolded proteins were shown to aggregate. Furthermore, the induction of ER stress was demonstrated to be associated with histone acetylation and inhibition of the mammalian target of rapamycin pathway.
|
